Truist lowered the firm’s price target on Regeneron (REGN) to $1,126 from $1,137 and keeps a Buy rating on the shares after its Q3 results. Investor focus has been on Eylea and Eylea HD conversion, but the firm maintains that Regeneron’s broad pipeline across oncology, internal/genetic medicines, I&I and ophthalmology remains overlooked, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $1,215 from $1,260 at RBC Capital
- Regeneron selloff ‘overdone’ with pipeline catalysts coming, says Morgan Stanley
- Regeneron price target lowered to $800 from $820 at BofA
- Regeneron earnings selloff ‘serious overreaction,’ says Piper Sandler
- Regeneron price target lowered to $1,065 from $1,080 at Barclays